

# André Schmidt

38A Johan v Oldenbarneveltlaan  
Den Haag 2582NT  
Netherlands  
Tel: +31 648 54 26 25  
Tel (office): +31 85 489 4932  
e-mail: [aschmidt@proqr.com](mailto:aschmidt@proqr.com)

Nationality: German and Portuguese  
Born: 22<sup>nd</sup> March 1977, Hannover  
Marital status: married

## **Curriculum Vitae for ANDRÉ SCHMIDT**

### **Employment**

2015 – present ProQR Therapeutics (Leiden, NL), Director Molecular Biology;  
2014 – 2015 ProQR Therapeutics (Leiden, NL), Sr. Scientist;  
2014 ProQR Therapeutics (Leiden, NL), Scientist;

### **Education**

2008 - 2014 University of Texas Southwestern Medical Center (Dallas, Texas), Post-Doctoral Scholar in the laboratory of Dr. Philip J. Thomas, Department of Physiology;  
2002 - 2008 Faculdade de Ciencias Universidade de Lisboa / Instituto Nacional de Saude Dr. Ricardo Jorge (Portugal), PhD (*summa cum laude*, 17<sup>th</sup> of July 2008) in the area of Cystic Fibrosis, supervised by Dr. M. D. Amaral (FCUL, Portugal) and Dr. D.N. Sheppard (University of Bristol, UK), 3-4 months a year with Dr. D.N. Sheppard in 2002, 2003, 2004 and 2006;  
2001 - 2002 Faculdade de Ciencias Universidade de Lisboa / Instituto Nacional de Saude Dr. Ricardo Jorge (Portugal), junior researcher with Dr. M. D. Amaral;  
1998 - 1999 University of Bath / University of Bristol (U.K.), Diploma (8<sup>th</sup> of July 1999) in Crop Protection and project for Fine Agrochemicals;  
1995 - 1998 University of Bristol (U.K.), BSc (*Hons*, 25<sup>th</sup> of June 1998) in Biochemistry. Modules in: Genetics, Pathology, Microbiology, Chemistry;  
1983 - 1995 European School of Brussels I (Belgium), European Baccalauréat;

### **Publications**

#### **Articles:**

1. SCOTT-WARD, T.S., LI, H., SCHMIDT, A. & SHEPPARD, D.N. (2002). Direct Block of the CFTR Cl<sup>-</sup> channel by niflumic acid. *Journal of Cystic Fibrosis* **1**, S71.
2. SCOTT-WARD, T.S., LI, H., SCHMIDT, A. & SHEPPARD; D.N. (2002). Mechanism of niflumic acid inhibition in the human CFTR Cl<sup>-</sup> channel. *Journal of Physiology* **544P**, 15P.
3. SCOTT-WARD, T.S., LI, H., SCHMIDT, A., CAI, Z. & SHEPPARD, D.N. (2004): Direct block of the cystic fibrosis transmembrane conductance regulator Cl<sup>-</sup> channel by niflumic acid. *Molecular Membrane Biology* **3**(2003); 21-27.

## André Schmidt

4. CAI, Z., SCOTT-WARD, T.S., LI, H., SCHMIDT, A. & SHEPPARD, D.N. (2004): Strategies to investigate the mechanism of action of CFTR modulators. *Journal of Cystic Fibrosis* **3**(2004); 141-147.
5. ROXO-ROSA M., XU Z., SCHMIDT A., NETO M., CAI Z., SOARES C.M., SHEPPARD D.N., AMARAL M.D. (2006): Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. *Proc Natl Acad Sci U S A*. **103**(47):17891-6.
6. SOUSA M., OUSINGSAWAT J., SEITZ R., PUNTHEERANURAK S., REGALADO A., SCHMIDT A., GREGO T., JANSAKUL C., AMARAL M.D., SCHREIBER R., KUNZELMANN K. (2007): An extract from the medicinal plant *Phyllanthus acidus* and its isolated compounds induce airway chloride secretion: A potential treatment for cystic fibrosis. *Mol Pharmacol* **71**;366-376
7. PISSARRA LS, FARINHA CM, XU Z, SCHMIDT A, THIBODEAU PH, CAI Z, THOMAS PJ, SHEPPARD DN, AMARAL MD. (2008): Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. *Chem Biol*. **15** (1); 62-69.
8. SCHMIDT, A., HUGHES, L.K., CAI, Z., LI, H., AMARAL, M.D., SHEPPARD, D.N. (2008): Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance Cl<sup>-</sup> channel. *BJ Physiology* **153** (6); 1311-1323.
9. HUTT DM, HERMAN D, RODRIGUES AP, NOEL S, PILEWSKI JM, MATTESON J, HOCH B, KELLNER W, KELLY JW, SCHMIDT A, THOMAS PJ, MATSUMURA Y, SKACH WR, GENTZSCH M, RIORDAN JR, SORSCHER EJ, OKIYONEDA T, YATES JR 3RD, LUKACS GL, FRIZZELL RA, MANNING G, GOTTESFELD JM, BALCH WE. (2010): Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. *Nat Chem Biol*. **6** (1):25-33.
10. HOELEN H, KLEIZEN B, SCHMIDT A, RICHARDSON J, CHARITOU P, THOMAS PJ, BRAAKMAN I. (2010): The primary folding defect and rescue of  $\Delta$ F508 CFTR emerge during translation of the mutant domain. *PLoS One*. **5** (11):e15458.
11. MENDOZA JL, SCHMIDT A, THOMAS PJ. (2011): Introduction to section IV: biophysical methods to approach CFTR structure. *Methods Mol Biol*. **741**:321-7.
12. SCHMIDT A, MENDOZA JL, THOMAS PJ. (2011): Biochemical and biophysical approaches to probe CFTR structure. *Methods Mol Biol*. **741**:365-76.
13. MENDOZA JL, SCHMIDT A, LI Q, NUVAGA E, BARRETT T, BRIDGES RJ, FERANCHAK AP, BRAUTIGAM CA, THOMAS PJ. (2012): Requirements for efficient correction of  $\Delta$ F508 CFTR revealed by analyses of evolved sequences. *Cell* **148** (1-2):164-74.

### Posters and Talks presented at Conferences:

1. CAI, Z., LI, H., SCHMIDT, A. & SHEPPARD, D.N. (2002): Investigating the mechanism of action of CFTR blockers. (Poster presented at the Third Consensus Meeting Towards Validation of CFTR Gene Expression and Functional Assays. Sintra, Portugal, April 12-14, 2002).
2. HUGHES, L.K., ALTHAUS, J., LUNN, J.S., SCHMIDT, A., LI, H., CAI, Z., PENQUE, D., AMARAL, M.D. & SHEPPARD, D.N. (2003): Analysis of the effect of genistein on the expression and function of wild-type and F508del CFTR. (Poster at the Fourth Consensus Meeting Towards Validation of CFTR Gene Expression and Functional Assays. Cascais, Portugal, April 10-13, 2003).
3. HUGHES, L.K., ALTHAUS, J., LUNN, J.S., SCHMIDT, A., LI, H., CAI, Z., PENQUE, D., AMARAL, M.D. & SHEPPARD, D.N. (2003): Analysis of the effect of genistein on the

## André Schmidt

expression and function of wild-type and F508del CFTR. (*Poster at the North American Cystic Fibrosis Conference, Anaheim, USA, October 3-6, 2003*).

4. ROXO-ROSA, M., SOARES, C.M., NETO, M., SCHMIDT, A., CAI, Z., PENQUE, D., SHEPPARD, D.N. & AMARAL, M.D. (2004): G550E and 4RK rescue CF-associated mutations in NBD1 other than F508del. (*Poster at the North American Cystic Fibrosis Conference, St. Louis, USA, October 14-17,2004*).
5. ROXO-ROSA M., XU Z., SCHMIDT A., NETO M., CAI Z., SOARES C.M., SHEPPARD D.N., AMARAL M.D. (2006): The Revertant Mutants G550E and 4RK Rescue Cystic Fibrosis Mutants in the First Nucleotide-Binding Domain by Different Mechanisms. (*Poster at the European Cystic Fibrosis Society and the Physiological Society Joint Meeting, Carvoeiro, Portugal, April 19-23, 2006*). Best Poster Award to presenting authors ZX and AS.
6. SCHMIDT A. & AMARAL M.D. (2006): Two distinct F508del Revertants are differently affected by a small corrector molecule. (*Poster at the North American Cystic Fibrosis Conference ,Denver, USA, November 2 - 5, 2006*).
7. SCHMIDT A. & AMARAL M.D. (2007) Investigation of the Mechanism of Action of Several Small Corrector Molecules by Means of F508DEL-CFTR Genetic Revertants (*Oral presentation at the European Cystic Fibrosis Society Conference, Tavira, Portugal, April 25 -29*).
8. SCHMIDT A., SOUSA M., KUNZELMANN K., AMARAL M.D (2008) Investigation of the Mechanism of Action of Several Small Molecules in BHK cells and Human Native Tissues. (*Poster at the European Cystic Fibrosis Society Conference, Regua, Portugal, April 9 - 13*).
9. SCHMIDT A., MILLEN L., RICHARDSON J., CASPA E., THOMAS P.J. (2009) Interaction of Small Molecules with CFTR (*Poster at the North American Cystic Fibrosis Conference, Minneapolis, USA, October 14 - 17*).
10. SCHMIDT A., MENDOZA J.L., MILLEN L., THOMAS P.J. (2011) Methods to establish Mechanism of Corrector Action (*Oral presentation at the North American Cystic Fibrosis Conference, Anaheim, USA, November 3 -5*).
11. SCHMIDT A., MILLEN L., MENDOZA J.L., FULLER M., CHENG Y., MILLER G.A., WIGLEY W.C., BRIDGES R.J., THOMAS P.J. (2012) Mechanistic Studies of CFTR Correctors (*Poster at the North American Cystic Fibrosis Conference, Orlando, USA, October 17-19*).
12. SCHMIDT A., MILLEN L., MENDOZA J.L., FULLER M., CHENG Y., MILLER G.A., WIGLEY W.C., BRIDGES R.J., THOMAS P.J. (2013) Mechanistic Studies of CFTR Correctors (*Oral presentation at the European Cystic Fibrosis Conference, Malaga, Spain, March 20-23*).
13. SCHMIDT A., MILLEN L., HARNESS-BRUMLEY C., HUERTA C., MENDOZA J.L., CHENG Y., MILLER G.A., WIGLEY W.C., BRIDGES R.J., THOMAS P.J. (2013) Mechanistic Studies of CFTR Correctors (*Poster presentation at the North American Cystic Fibrosis Conference, Salt Lake City, USA, October 17-20*).

### **Languages spoken fluently**

Native bilingual in *German* and *Portuguese*, Portuguese-Spanish mother and German father;  
*French* taught since the age of six at school and lived in a french speaking environment;  
*English* taught since the age of twelve and four years of study in the U.K.; and 5 years U.S.  
*Spanish* taught since the age of thirteen and several prolonged visits to Spain;